Bederra Corporation to acquire Texas Mobile Health

NewsGuard 100/100 Score

Bederra Corporation (PINKSHEETS: BEDA), a Houston, Texas based diversified medical services provider, announced that the company has signed a Letter of Intent to acquire Texas Mobile Health, Inc.

Texas Mobile Health, Inc. provides mobile diagnostic services such as Eko Cardiograms, Pulmonary Function tests, Vascular Studies and Event Monitoring to physician offices, clinics and nursing homes. By acquiring Texas Mobile Health, Bederra will be able to provide ICAVL certified facilities and be able to gain further revenues under the ICAVL certification, which is now a requirement of Medicare and certain private insurance companies.

The acquisition is estimated to generate revenues in the $3 million range with plans to add several additional services that could double this volume. Due to some anticipated changes in Medicare beginning in January 2010, many existing physician offices will not be able to provide in-house services such as those provided by Texas Mobile Health due to certification requirements. Therefore, there will be a greater market for companies such as Texas Mobile Health to fulfill this need.

This acquisition will mark the horizontal diversification of Bederra Corporation and complements its current suite of diagnostic services with another operational and revenue generating model. Texas Mobile Health will enable Bederra clients in need of diagnostic services, but unable to travel, to receive those services in the comfort and safety of their own homes.

Source:

Bederra Corporation

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study unveils novel bladder cancer diagnostic model based on key mitochondrial genes